| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 August 1994 | Volume 121 Issue 4 | Pages 281-288
Purpose: To evaluate treatments for hyperthyroid disease.
Data Sources: Selected studies published during the last 20 years addressing the diagnosis, causes, and treatment of hyperthyroid disease.
Study Selection: Studies were chosen based on their usefulness in addressing specific points in the treatment of hyperthyroid disease.
Data Extraction: Various treatment principles extracted from the references form the basis for the conclusions and recommendations made here.
Results: Hyperthyroid disease is a common endocrine disease. Although Graves disease is the most common cause of thyrotoxicosis, other primary and secondary causes exist. With classic signs and symptoms accompanied by confirmatory laboratory measures of thyroid hyperfunction, the diagnosis can be established firmly. Radioiodine is the preferred method to treat Graves disease; however, recent data concerning treatment with a combination of propylthiouracil and thyroxine require further evaluation to establish its efficacy. Radioiodine is also the preferred treatment for the other forms of hyperthyroid disease; however, patient-specific considerations in both may require patient-tailored therapies.
Conclusions: Hyperthyroid disease can be treated definitively for most patients. Palliative therapy with ß-adrenergic blockade is useful in some patients. Further studies are needed to determine whether more recently described treatments have improved efficacy and whether therapy directed specifically at the underlying immunologic cause of Graves disease can be used successfully.
Author and Article Information
From North Shore University Hospital, Cornell University Medical College, and New York Hospital-Cornell Medical Center, New York, New York; Merck & Co., Inc., Whitehouse Station, New Jersey.
DIAGNOSIS AND TREATMENT
Treatment of Hyperthyroid Disease
![]()
Requests for Reprints: Irwin Klein, MD, Chief, Division of Endocrinology, North Shore University Hospital/Cornell University Medical College, 300 Community Drive, Manhasset, NY 11030.
This article has been cited by other articles:
![]() |
I. Klein and S. Danzi Thyroid Disease and the Heart Circulation, October 9, 2007; 116(15): 1725 - 1735. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Squizzato, V.E.A. Gerdes, D.P.M. Brandjes, H.R. Buller, and J. Stam Thyroid Diseases and Cerebrovascular Disease Stroke, October 1, 2005; 36(10): 2302 - 2310. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter Cardioselective {beta}-Blockers in Patients with Reactive Airway Disease: A Meta-Analysis Ann Intern Med, November 5, 2002; 137(9): 715 - 725. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Klein and K. Ojamaa Thyroid Hormone and the Cardiovascular System N. Engl. J. Med., February 15, 2001; 344(7): 501 - 509. [Full Text] [PDF] |
||||
![]() |
E. Ron, M. M. Doody, D. V. Becker, A. B. Brill, R. E. Curtis, M. B. Goldman, B. S. H. Harris III, D. A. Hoffman, W. M. McConahey, H. R. Maxon, et al. Cancer Mortality Following Treatment for Adult Hyperthyroidism JAMA, July 22, 1998; 280(4): 347 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lucas, I. Salinas, F. Rius, E. Pizarro, M.L. Granada, M. Foz, and A. SanmartI Medical Therapy of Graves' Disease: Does Thyroxine Prevent Recurrence of Hyperthyroidism? J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2410 - 2413. [Abstract] [Full Text] [PDF] |
||||